Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Capital Employed (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Return on Capital Employed for 2 consecutive years, with 0.18% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 10.0% to 0.18% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.18% through Dec 2025, down 10.0% year-over-year, with the annual reading at 0.14% for FY2025, 7.0% down from the prior year.
  • Return on Capital Employed hit 0.18% in Q4 2025 for Silence Therapeutics, up from 0.22% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.08% in Q4 2024 to a low of 0.22% in Q3 2025.